Comparisons of Serum Sclerostin Levels among Patients with Postmenopausal Osteoporosis, Primary Hyperparathyroidism and Osteomalacia
Comparisons of Serum Sclerostin Levels among Patients with Postmenopausal Osteoporosis, Primary Hyperparathyroidism and Osteomalacia
复制标题
DOI：
10.1055/s-0031-1275661
复制
发表时间：
2011-07-01
影响因子：
1.8
通讯作者：
Seino, S.
中科院分区：
文献类型：
--
作者：
Kaji, H.;Imanishi, Y.;Seino, S.
WNT-β-连环蛋白信号对骨形成很重要。硬化素主要通过抑制这一信号抑制骨形成，一些研究表明，抑制硬化素的表达有助于甲状旁腺激素(PTH)的骨合成代谢作用。因此，我们用酶联免疫分析法检测了18例绝经后骨质疏松症患者、9例原发性甲状旁腺功能亢进症(PHPT)患者和7例骨软化症患者的血清硬化素水平。与绝经后骨质疏松症患者相比，PHPT组患者血清硬化蛋白水平显著降低。此外，与绝经后骨质疏松症患者相比，肿瘤引起的骨软化组的血清硬化素水平显著降低，而无肿瘤的骨软化组的血清硬化素水平无明显变化。在PHPT患者中，血清硬化素水平与血钙和甲状旁腺素水平呈显著负相关。在绝经后骨质疏松症患者中，血清硬化素水平与血钙、肌酐水平呈显著正相关。总而言之，与绝经后骨质疏松症患者相比，我们发现绝经后PHPT患者的血清硬化素水平可能通过内源性甲状旁腺素升高而降低。
Wnt-beta-catenin signaling is important for bone formation. Sclerostin inhibits bone formation mainly by suppressing this signal, and several studies suggest that the suppression of sclerostin expression contributes to the bone anabolic action of parathyroid hormone (PTH). We therefore examined serum sclerostin levels using enzyme-linked immunosolvent assay in 18 patients with postmenopausal osteoporosis, 9 postmenopausal women with primary hyperparathyroidism (pHPT) and 7 patients with osteomalacia. Serum levels of sclerostin were significantly lower in the group with pHPT, compared with those with postmenopausal osteoporosis. Moreover, serum sclerostin levels were significantly lower in the group with tumor-induced osteomalacia, but not in the group with osteomalacia without tumor, compared with those with postmenopausal osteoporosis. In patients with pHPT, serum sclerostin levels were significantly and negatively correlated to serum calcium and PTH levels. In patients with postmenopausal osteoporosis, serum levels of sclerostin levels were significantly and positively related to serum calcium and creatinine levels. In conclusion, we showed that serum sclerostin levels are decreased presumably through endogenous PTH elevation in postmenopausal women with pHPT, compared with the patients with postmenopausal osteoporosis.